-
公开(公告)号：CA2514681C
公开(公告)日：2011-04-05
申请号：CA2514681
申请日：1997-11-04
Applicant: CHILDRENS MEDICAL CENTER
Inventor： D AMATO ROBERT J
IPC: A61K31/454 , C07D491/044 , A61K31/00 , A61K31/16 , A61K31/167 , A61K31/185 , A61K31/19 , A61K31/192 , A61K31/194 , A61K31/196 , A61K31/20 , A61K31/395 , A61K31/40 , A61K31/4015 , A61K31/403 , A61K31/405 , A61K31/4152 , A61K31/4164 , A61K31/425 , A61K31/44 , A61K31/445 , A61K31/45 , A61K31/47 , A61K31/5377 , A61K31/56 , A61K31/573 , A61K31/60 , A61K31/621 , A61K45/06 , A61P1/00 , A61P1/04 , A61P7/06 , A61P9/00 , A61P9/10 , A61P19/02 , A61P19/06 , A61P27/02 , A61P27/06 , A61P29/00 , A61P31/04 , A61P31/12 , A61P35/00 , A61P35/02 , A61P37/06 , C07D207/416 , C07D211/88 , C07D401/04
Abstract: The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products have been shown to inhibit angiogenesis and to treat disease states resulting from angiogenesis. Additionally, antiinflammatory drugs, such as steroids and NSAIDs can inhibit angiogenesis dependent diseases either alone or in combination with thalidomide and related compounds. Importantly, thee compounds can be administered orally.
-
公开(公告)号：DK1920773T3
公开(公告)日：2011-03-28
申请号：DK07121971
申请日：1997-11-04
Applicant: CHILDRENS MEDICAL CENTER
Inventor： D AMATO ROBERT J
IPC: A61K31/44 , C07D491/044 , A61K31/00 , A61K31/16 , A61K31/167 , A61K31/185 , A61K31/19 , A61K31/192 , A61K31/194 , A61K31/196 , A61K31/20 , A61K31/395 , A61K31/40 , A61K31/4015 , A61K31/403 , A61K31/405 , A61K31/4152 , A61K31/4164 , A61K31/425 , A61K31/445 , A61K31/45 , A61K31/454 , A61K31/47 , A61K31/5377 , A61K31/56 , A61K31/573 , A61K31/60 , A61K31/621 , A61K45/06 , A61P1/00 , A61P1/04 , A61P7/06 , A61P9/00 , A61P9/10 , A61P19/02 , A61P19/06 , A61P27/02 , A61P27/06 , A61P29/00 , A61P31/04 , A61P31/12 , A61P35/00 , A61P35/02 , A61P37/06 , A61P43/00 , C07D207/416 , C07D211/88 , C07D401/04
-
公开(公告)号：AT493983T
公开(公告)日：2011-01-15
申请号：AT07121971
申请日：1997-11-04
Applicant: CHILDRENS MEDICAL CENTER
Inventor： D AMATO ROBERT J
IPC: A61K31/44 , C07D491/044 , A61K31/00 , A61K31/16 , A61K31/167 , A61K31/185 , A61K31/19 , A61K31/192 , A61K31/194 , A61K31/196 , A61K31/20 , A61K31/395 , A61K31/40 , A61K31/4015 , A61K31/403 , A61K31/405 , A61K31/4152 , A61K31/4164 , A61K31/425 , A61K31/445 , A61K31/45 , A61K31/454 , A61K31/47 , A61K31/5377 , A61K31/56 , A61K31/573 , A61K31/60 , A61K31/621 , A61K45/06 , A61P1/00 , A61P1/04 , A61P7/06 , A61P9/00 , A61P9/10 , A61P19/02 , A61P19/06 , A61P27/02 , A61P27/06 , A61P29/00 , A61P31/04 , A61P31/12 , A61P35/00 , A61P35/02 , A61P37/06 , A61P43/00 , C07D207/416 , C07D211/88 , C07D401/04
Abstract: The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products have been shown to inhibit angiogenesis and to treat disease states resulting from angiogenesis. Additionally, anti-inflammatory drugs, such as steroids and NSAIDs can inhibit angiogenesis dependent diseases either alone or in combination with thalidomide and related compounds. Importantly, these compounds can be administered orally.
-
公开(公告)号：DE69734290T2
公开(公告)日：2006-07-06
申请号：DE69734290
申请日：1997-11-04
Applicant: CHILDRENS MEDICAL CENTER
Inventor： D AMATO ROBERT J
IPC: A61K31/44 , C07D491/044 , A61K31/00 , A61K31/16 , A61K31/167 , A61K31/185 , A61K31/19 , A61K31/192 , A61K31/194 , A61K31/196 , A61K31/20 , A61K31/395 , A61K31/40 , A61K31/4015 , A61K31/403 , A61K31/405 , A61K31/4152 , A61K31/4164 , A61K31/425 , A61K31/445 , A61K31/45 , A61K31/454 , A61K31/47 , A61K31/5377 , A61K31/56 , A61K31/573 , A61K31/60 , A61K31/621 , A61K45/06 , A61P1/00 , A61P1/04 , A61P7/06 , A61P9/00 , A61P9/10 , A61P19/02 , A61P19/06 , A61P27/02 , A61P27/06 , A61P29/00 , A61P31/04 , A61P31/12 , A61P35/00 , A61P35/02 , A61P37/06 , C07D207/416 , C07D211/88 , C07D401/04
Abstract: The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products have been shown to inhibit angiogenesis and to treat disease states resulting from angiogenesis. Additionally, anti-inflammatory drugs, such as steroids and NSAIDs can inhibit angiogenesis dependent diseases either alone or in combination with thalidomide and related compounds. Importantly, these compounds can be administered orally.
-
公开(公告)号：ES2253787T3
公开(公告)日：2006-06-01
申请号：ES97946884
申请日：1997-11-04
Applicant: CHILDRENS MEDICAL CENTER
Inventor： D AMATO ROBERT J
IPC: C07D491/044 , A61K31/00 , A61K31/16 , A61K31/167 , A61K31/185 , A61K31/19 , A61K31/192 , A61K31/194 , A61K31/196 , A61K31/20 , A61K31/395 , A61K31/40 , A61K31/4015 , A61K31/403 , A61K31/405 , A61K31/4152 , A61K31/4164 , A61K31/425 , A61K31/44 , A61K31/445 , A61K31/45 , A61K31/454 , A61K31/47 , A61K31/5377 , A61K31/56 , A61K31/573 , A61K31/60 , A61K31/621 , A61K45/06 , A61P1/00 , A61P1/04 , A61P7/06 , A61P9/00 , A61P9/10 , A61P19/02 , A61P19/06 , A61P27/02 , A61P27/06 , A61P29/00 , A61P31/04 , A61P31/12 , A61P35/00 , A61P35/02 , A61P37/06 , C07D207/416 , C07D211/88 , C07D401/04 , A61K31/62
Abstract: LA INVENCION COMPRENDE UN GRUPO DE COMPUESTOS QUE INHIBEN DE FORMA EFECTIVA LA ANGIOGENESIS. MAS ESPECIFICAMENTE, LA TALIDOMIDA Y DIFERENTES COMPUESTOS RELACIONADOS TALES COMO PRECURSORES, ANALOGOS, METABOLITOS Y PRODUCTOS DE HIDROLISIS DE LA TALIDOMIDA HAN MOSTRADO QUE INHIBEN LA ANGIOGENESIS Y QUE SON UTILES PARA EL TRATAMIENTO DE ESTADOS PATOLOGICOS GENERADOS POR LA ANGIOGENESIS. ADICIONALMENTE, MEDICAMENTOS ANTIINFLAMATORIOS, TALES COMO ESTEROIDES Y NSAIDS PUEDEN INHIBIR ENFERMEDADES QUE DEPENDEN DE LA ANGIOGENESIS BIEN SOLOS O EN COMBINACION CON LA TALIDOMIDA Y LOS COMPUESTOS RELACIONADOS. UN HECHO IMPORTANTE ES QUE LOS COMPUESTOS PUEDEN ADMINISTRARSE ORALMENTE.
-
Patent Agency Ranking
公开(公告)号：DK0963200T3
公开(公告)日：2005-10-24
申请号：DK97946884
申请日：1997-11-04
Applicant: CHILDRENS MEDICAL CENTER
Inventor： D AMATO ROBERT J
IPC: C07D491/044 , A61K31/00 , A61K31/16 , A61K31/167 , A61K31/185 , A61K31/19 , A61K31/192 , A61K31/194 , A61K31/196 , A61K31/20 , A61K31/395 , A61K31/40 , A61K31/4015 , A61K31/403 , A61K31/405 , A61K31/4152 , A61K31/4164 , A61K31/425 , A61K31/44 , A61K31/445 , A61K31/45 , A61K31/454 , A61K31/47 , A61K31/5377 , A61K31/56 , A61K31/573 , A61K31/60 , A61K31/621 , A61K45/06 , A61P1/00 , A61P1/04 , A61P7/06 , A61P9/00 , A61P9/10 , A61P19/02 , A61P19/06 , A61P27/02 , A61P27/06 , A61P29/00 , A61P31/04 , A61P31/12 , A61P35/00 , A61P35/02 , A61P37/06 , C07D207/416 , C07D211/88 , C07D401/04 , A61K31/62
Abstract: The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products have been shown to inhibit angiogenesis and to treat disease states resulting from angiogenesis. Additionally, anti-inflammatory drugs, such as steroids and NSAIDs can inhibit angiogenesis dependent diseases either alone or in combination with thalidomide and related compounds. Importantly, these compounds can be administered orally.
-
公开(公告)号：AU746713B2
公开(公告)日：2002-05-02
申请号：AU5197398
申请日：1997-11-04
Applicant: CHILDRENS MEDICAL CENTER
Inventor： D AMATO ROBERT J
IPC: C07D491/044 , A61K31/00 , A61K31/16 , A61K31/167 , A61K31/185 , A61K31/19 , A61K31/192 , A61K31/194 , A61K31/196 , A61K31/20 , A61K31/395 , A61K31/40 , A61K31/4015 , A61K31/403 , A61K31/405 , A61K31/4152 , A61K31/4164 , A61K31/425 , A61K31/44 , A61K31/445 , A61K31/45 , A61K31/454 , A61K31/47 , A61K31/5377 , A61K31/56 , A61K31/573 , A61K31/60 , A61K31/621 , A61K45/06 , A61P1/00 , A61P1/04 , A61P7/06 , A61P9/00 , A61P9/10 , A61P19/02 , A61P19/06 , A61P27/02 , A61P27/06 , A61P29/00 , A61P31/04 , A61P31/12 , A61P35/00 , A61P35/02 , A61P37/06 , C07D207/416 , C07D211/88 , C07D401/04
Abstract: The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products have been shown to inhibit angiogenesis and to treat disease states resulting from angiogenesis. Additionally, anti-inflammatory drugs, such as steroids and NSAIDs can inhibit angiogenesis dependent diseases either alone or in combination with thalidomide and related compounds. Importantly, these compounds can be administered orally.
-
公开(公告)号：CA2270887A1
公开(公告)日：1998-05-14
申请号：CA2270887
申请日：1997-11-04
Applicant: CHILDRENS MEDICAL CENTER
Inventor： D AMATO ROBERT J
IPC: C07D491/044 , A61K31/00 , A61K31/16 , A61K31/167 , A61K31/185 , A61K31/19 , A61K31/192 , A61K31/194 , A61K31/196 , A61K31/20 , A61K31/395 , A61K31/40 , A61K31/4015 , A61K31/403 , A61K31/405 , A61K31/4152 , A61K31/4164 , A61K31/425 , A61K31/44 , A61K31/445 , A61K31/45 , A61K31/454 , A61K31/47 , A61K31/5377 , A61K31/56 , A61K31/573 , A61K31/60 , A61K31/621 , A61K45/06 , A61P1/00 , A61P1/04 , A61P7/06 , A61P9/00 , A61P9/10 , A61P19/02 , A61P19/06 , A61P27/02 , A61P27/06 , A61P29/00 , A61P31/04 , A61P31/12 , A61P35/00 , A61P35/02 , A61P37/06 , C07D207/416 , C07D211/88 , C07D401/04 , A61K31/33
Abstract: The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products have been shown to inhibit angiogenesis and to treat disease states resulting from angiogenesis. Additionally, antiinflammatory drugs, such as steroids and NSAIDs can inhibit angiogenesis dependent diseases either alone or in combination with thalidomide and related compounds. Importantly, these compounds can be administered orally.
-
公开(公告)号：CA2430669C
公开(公告)日：2011-06-14
申请号：CA2430669
申请日：2001-11-30
Applicant: CHILDRENS MEDICAL CENTER
Inventor： TRESTON ANTHONY , SHAH JAMSHED H , D AMATO ROBERT J , HUNSUCKER KIMBERLY A , ROUGAS JOHN , CONNER BARRY P , PRIBLUDA VICTOR , SWARTZ GLENN M
IPC: A61K31/4035 , C07D401/04 , A61K31/454 , A61P1/16 , A61P1/18 , A61P3/02 , A61P3/10 , A61P5/00 , A61P7/00 , A61P7/06 , A61P9/00 , A61P9/10 , A61P13/08 , A61P15/00 , A61P17/00 , A61P17/02 , A61P17/06 , A61P19/02 , A61P19/04 , A61P19/06 , A61P25/00 , A61P27/02 , A61P27/06 , A61P27/10 , A61P29/00 , A61P31/04 , A61P31/10 , A61P31/12 , A61P31/22 , A61P33/00 , A61P35/00 , A61P35/02 , A61P35/04 , A61P37/02
Abstract: The invention provides new and useful analogs of 3-amino-thalidomide. These analogs include S(-)-3-amino-thalidomide and R(+)-3-amino-thalidomide. The invention also provides processes for making these analogs. Further, the invention provides methods for inhibiting angiogenesis and treating angiogenesis-associated diseases, including cancer and macular degeneration, by administering these compounds.
-
公开(公告)号：AT405268T
公开(公告)日：2008-09-15
申请号：AT05014759
申请日：1997-11-04
Applicant: CHILDRENS MEDICAL CENTER
Inventor： D AMATO ROBERT J
IPC: A61K31/454 , C07D491/044 , A61K31/00 , A61K31/16 , A61K31/167 , A61K31/185 , A61K31/19 , A61K31/192 , A61K31/194 , A61K31/196 , A61K31/20 , A61K31/395 , A61K31/40 , A61K31/4015 , A61K31/403 , A61K31/405 , A61K31/4152 , A61K31/4164 , A61K31/425 , A61K31/44 , A61K31/445 , A61K31/45 , A61K31/47 , A61K31/5377 , A61K31/56 , A61K31/573 , A61K31/60 , A61K31/621 , A61K45/06 , A61P1/00 , A61P1/04 , A61P7/06 , A61P9/00 , A61P9/10 , A61P19/02 , A61P19/06 , A61P27/02 , A61P27/06 , A61P29/00 , A61P31/04 , A61P31/12 , A61P35/00 , A61P35/02 , A61P37/06 , C07D207/416 , C07D211/88 , C07D401/04
Abstract: The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, thalidomide and various related compounds such as thalidomide precursors, analogs, metabolites and hydrolysis products have been shown to inhibit angiogenesis and to treat disease states resulting from angiogenesis. Additionally, anti-inflammatory drugs, such as steroids and NSAIDs can inhibit angiogenesis dependent diseases either alone or in combination with thalidomide and related compounds. Importantly, these compounds can be administered orally.
-
-
-
-
-
-
-
-
-
Search Results
42
records
(took 0.023 seconds)
